Clinical Trial Update: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing trastuzumab deruxtecan versus CDK4/6 inhibitor–based endocrine therapy as first-line treatment for HR-positive, HER2-low/ultralow adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Low Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor-based endocrine therapy
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: MedSIR | Conditions: Advanced Breast Cancer, Advanced Breast Carcinoma | Phase 2 | Status: RECRUITING